

Table 3: Estimated effect of full use of vaccines currently recommended for adults

Disease	Estimated Annual Deaths (no.)	Estimated Vaccine Efficacy ¹ (%)	Current Vaccine Utilization ² (%)	Additional Preventable Deaths/Yr ³ (no.)
Influenza	20,000 ⁴	70	41	8,260
Pneumococcal infection	40,000	60	20	19,200
Hepatitis B	5,000	90	10 ⁵	4,050
Tetanus-diphtheria	<25	99	40 ⁶	<15
Measles, mumps, rubella	<30	95	Variable	<30
Travelers' diseases (cholera, typhoid, Japanese encephalitis, yellow fever, poliomyelitis, and rabies)	<10	NA ⁷	NA ⁷	<10

Source: New England Journal of Medicine 1993; 328:1252-8.

¹Indicates efficacy in immunocompetent adults. Among elderly and immunocompromised patients, estimated efficacy may be lower.

²The percentage of targeted groups immunized according to current recommendations. Rates vary among groups. Data for influenza and pneumococcal vaccines were obtained from the 1991 National Health Interview Survey and apply to persons ≥ 65 years of age.

³Calculated as follows: (potential additional vaccine utilization) x (estimated vaccine efficacy) x (estimated annual deaths).

⁴Variable (range is 0 to 40,000).

⁵Highly variable (range is 1 to 60 percent) among groups.

⁶This estimate is based on seroprevalence data.

⁷NA signifies that an average figure would be not applicable.